These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28100595)

  • 1. Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.
    Giorgi Rossi P; Bisanzi S; Allia E; Mongia A; Carozzi F; Gillio-Tos A; De Marco L; Ronco G; Gustinucci D; Del Mistro A; Frayle H; Iossa A; Fantacci G; Pompeo G; Cesarini E; Bulletti S; Passamonti B; Rizzi M; Penon MG; Barca A; Benevolo M
    J Clin Microbiol; 2017 Apr; 55(4):1056-1065. PubMed ID: 28100595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
    Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
    J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
    Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
    J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus mRNA testing for the detection of anal high-grade squamous intraepithelial lesions in men who have sex with men infected with HIV.
    Sendagorta E; Romero MP; Bernardino JI; Beato MJ; Alvarez-Gallego M; Herranz P
    J Med Virol; 2015 Aug; 87(8):1397-403. PubMed ID: 25940055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test.
    Benevolo M; Vocaturo A; Caraceni D; French D; Rosini S; Zappacosta R; Terrenato I; Ciccocioppo L; Frega A; Giorgi Rossi P
    J Clin Microbiol; 2011 Jul; 49(7):2643-50. PubMed ID: 21525231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test.
    Shen Y; Gong J; He Y; Cheng G; Okunieff P; Li X
    J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China.
    Zhang J; Liu G; Yang D; Cui X; Wang C; Wang D; Piao H
    Front Cell Infect Microbiol; 2024; 14():1428071. PubMed ID: 39268482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany.
    Iftner T; Neis KJ; Castanon A; Landy R; Holz B; Woll-Herrmann A; Iftner A; Staebler A; Wallwiener D; Hann von Weyhern C; Neis F; Haedicke-Jarboui J; Martus P; Brucker S; Henes M; Sasieni P
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women.
    Yao YL; Tian QF; Cheng B; Cheng YF; Ye J; Lu WG
    J Zhejiang Univ Sci B; 2017 Mar.; 18(3):256-262. PubMed ID: 28271661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
    Giorgi Rossi P; Carozzi F; Ronco G; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Mancuso P; Venturelli F; Benevolo M;
    J Natl Cancer Inst; 2021 Mar; 113(3):292-300. PubMed ID: 32745170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
    Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
    Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
    Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
    J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
    Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women.
    Bruno MT; Ferrara M; Fava V; Rapisarda A; Coco A
    Virol J; 2018 Mar; 15(1):52. PubMed ID: 29587778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of the E6/E7 mRNA-based Optimygene HR-HPV RT-qDx assay for cervical cancer screening.
    Wang HY; Kim H; Park KH
    Int J Infect Dis; 2019 Jan; 78():22-30. PubMed ID: 30248464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.